|
Volumn 3, Issue SUPPL. 2, 2002, Pages
|
Docetaxel/platinum in advanced non-small-cell lung cancer: Recent randomized trials
|
Author keywords
Combination therapy; Docetaxel; ERCC 1 expression; Gemcitabine; Genotyping; Platinum compounds; tubulin alterations
|
Indexed keywords
CARBOPLATIN;
CETUXIMAB;
CISPLATIN;
DOCETAXEL;
EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;
ERLOTINIB;
GEFITINIB;
GEMCITABINE;
GRANULOCYTE COLONY STIMULATING FACTOR;
IRINOTECAN;
NAVELBINE;
PACLITAXEL;
PLATINUM;
PROTEIN TYROSINE KINASE INHIBITOR;
UNCLASSIFIED DRUG;
VINDESINE;
ADULT;
ADVANCED CANCER;
AGED;
ANEMIA;
AREA UNDER THE CURVE;
ARTICLE;
ASTHENIA;
BLOOD TOXICITY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIARRHEA;
DRUG CYTOTOXICITY;
DRUG EFFICACY;
DRUG TOLERABILITY;
FEBRILE NEUTROPENIA;
FEMALE;
HUMAN;
INFECTION;
LUNG NON SMALL CELL CANCER;
MAJOR CLINICAL STUDY;
MALE;
METASTASIS;
NAUSEA AND VOMITING;
NEUTROPENIA;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIAL;
|
EID: 0036306446
PISSN: 15257304
EISSN: None
Source Type: Journal
DOI: 10.3816/CLC.2002.s.007 Document Type: Article |
Times cited : (2)
|
References (25)
|